influential [idcn]
Hormone replacement therapy [topp]
regimens [inpr]
Oral [spco]
Estradiol [horm, phsu, strd]
valerate [lipd]
Cyproterone Acetate [phsu, strd]
Transdermal [ftcn]
Estradiol [horm, phsu, strd]
Oral [spco]
Dydrogesterone [horm, phsu, strd]
Lipid Metabolism [moft]
Objective [inpr]
influential [idcn]
Lipid Metabolism [moft]
Discontinuous [tmco]
Combined [qlco]
Hormone replacement therapy [topp]
regimens [inpr]
Study Design [resa]
Open [spco]
randomized [resa]
Study [mnob]
Women [popg]
Full [qlco]
Lipid [lipd]
Profile [lbpr]
Including [ftcn]
Lp(a) [aapp, bacs]
Liver Function Tests [lbpr]
Assessed [acty]
Fasting state [fndg]
End [spco]
treatment [ftcn]
Cycle [tmco]
Group A [clas]
treated [topp]
mg% [qnco]
Oestradiol valerate [horm, phsu, strd]
days [tmco]
Combined [qlco]
mg% [qnco]
Cyproterone Acetate [phsu, strd]
days [tmco]
Group [idcn]
treated [topp]
Patch [fndg]
Releasing [ftcn]
mU/g [qnco]
Estradiol [horm, phsu, strd]
Daily [tmco]
Twice [inpr]
3 Weeks [tmco]
Combined [qlco]
mg% [qnco]
Dydrogesterone [horm, phsu, strd]
days [tmco]
Orally [spco]
statistical analysis [resa]
Side [spco]
baseline [bodm]
Adjusted [ftcn]
Means [cnce]
Lipid [lipd]
Parameters [fndg]
Rank [inpr]
Transformation [celf]
Lipoprotein (a) [aapp, bacs]
Lp(a) [aapp, bacs]
Performed [ftcn]
Group [idcn]
Statistically [ocdi]
Trial [resa]
COMPLETED [qlco]
Subject [grup]
Protocol Violation [resa]
Occurred [acty]
Cases [ftcn]
Twelve [qnco]
Subject [grup]
divided [ftcn]
Group [idcn]
Dropped [acty]
Out [spco]
Adverse reactions [fndg]
Treatments [topp]
effective [qlco]
treatment [ftcn]
Climacteric [orgf]
complaints [fndg]
Liver Function Tests [lbpr]
treatment [ftcn]
Normal [qlco]
Group [idcn]
Group A [clas]
statistically significant [qnco]
P NOS [aapp, imft]
Decrease [qlco]
baseline [bodm]
Observed [ftcn]
Adjusted [ftcn]
Means [cnce]
Following [tmco]
Parameters [fndg]
treatment [ftcn]
Cycle [tmco]
Total Cholesterol [lbpr]
Low Density Lipoprotein Cholesterol [bacs, strd]
Low Density Lipoprotein Cholesterol [bacs, strd]
High Density Lipoprotein Cholesterol [bacs, lipd]
Ratio [qnco]
ldl hdl ratio [lbtr]
Triglyceride level [lbtr]
Increased [qnco]
P NOS [aapp, imft]
treatment [ftcn]
Cycle [tmco]
Group [idcn]
Lipid [lipd]
Parameters [fndg]
exception [idcn]
Apolipoprotein A-II [aapp, bacs]
Decreased [qnco]
treatment [ftcn]
Cycle [tmco]
Unchanged [fndg]
therapy [ftcn]
statistically significant [qnco]
variables [qlco]
Group [idcn]
treatment [ftcn]
Cycle [tmco]
exception [idcn]
Total Cholesterol [lbpr]
treatment [ftcn]
Cycle [tmco]
treatment [ftcn]
Cycle [tmco]
Lp(a) [aapp, bacs]
Decreased [qnco]
Group A [clas]
Compared [acty]
baseline [bodm]
months [tmco]
Decrease [qlco]
Reaching [orgf]
Statistical Significance [qnco]
Group [idcn]
Lp(a) [aapp, bacs]
Slight [qlco]
Not significant [fndg]
Statistically [ocdi]
treatment [ftcn]
Cycle [tmco]
Group [idcn]
Reach [orgf]
randomized [resa]
Comparative Study [inpr]
Combined [qlco]
Oral [spco]
Hormone replacement therapy [topp]
Regimen [topp]
Oestradiol valerate [horm, phsu, strd]
mg% [qnco]
Daily [tmco]
days [tmco]
Cyproterone Acetate [phsu, strd]
mg% [qnco]
Daily [tmco]
days [tmco]
Induced [ftcn]
Lipid [lipd]
Pattern [spco]
Probably [idcn]
Lp(a) [aapp, bacs]
View [spco]
Prevention [topp]
Cardiovascular disease [dsyn]
Lipid [lipd]
Pattern [spco]
Induced [ftcn]
Combined [qlco]
Regimen [topp]
Transdermal [ftcn]
17 beta-Estradiol [horm, phsu, strd]
mU/g [qnco]
Twice weekly [tmco]
weeks [tmco]
Oral [spco]
Dydrogesterone [horm, phsu, strd]
mg% [qnco]
Daily [tmco]
days [tmco]
